Revolutionizing Sarcoma Care: The Controversial Role of Next-Generation Sequencing
Next-generation sequencing (NGS) has emerged as a game-changer in oncology, promising to unlock 'tumor-agnostic' therapies that could transform cancer treatment. But here's where it gets controversial: despite its potential, a groundbreaking consensus statement reveals that evidence does not support the routine use of NGS in sarcoma diagnosis and treatment—at least not yet. This raises a critical question: are we rushing to adopt cutting-edge technology before fully understanding its implications?
Sarcomas are notoriously complex, representing one of the most diverse groups of cancers with over 70 distinct subtypes and numerous ultra-rare variants. While their genetic simplicity or complexity varies, most sarcomas share a strikingly low mutational burden, making precision oncology a daunting challenge. In recent years, the widespread availability of NGS has sparked debates about its role in sarcoma care. A multidisciplinary panel of experts, led by César Serrano of the Vall d’Hebron Institute of Oncology, recently published a consensus review in JAMA Oncology (https://jamanetwork.com/journals/jamaoncology/fullarticle/2840002) that sheds light on this issue.
The Promise and Pitfalls of NGS in Sarcoma
NGS is hailed for its ability to identify biomarkers that could guide future therapies, but the consensus highlights a sobering reality: while NGS technologies are increasingly accessible, their routine use in sarcoma care lacks robust evidence. This is partly because sarcomas are either genomically simple (driven by fusions) or complex (with extensive rearrangements), making them less likely to harbor actionable mutations. For instance, studies show misdiagnosis rates of 10-25% when sarcomas are not reviewed by experts, underscoring the need for caution.
And this is the part most people miss: NGS is invaluable for identifying 'tumor-agnostic targets'—genetic traits that could respond to treatment regardless of the cancer's origin. It can also uncover heritable genetic predispositions, influencing treatment and risk management. However, the molecular understanding of sarcomas, especially ultra-rare subtypes, remains woefully inadequate. This knowledge gap, coupled with the rarity and heterogeneity of sarcomas, has left clinicians without clear guidelines on NGS use—until now.
Key Takeaways from the Consensus
The panel's most striking conclusion? Despite NGS's power to detect genetic alterations, only a fraction of sarcomas have actionable mutations, and the therapeutic benefits of matched treatments are limited. This prompts a thought-provoking question: are we overestimating the clinical utility of NGS in sarcoma care?
The consensus recommends sequencing all sarcomas in a research setting using pangenomic tools like whole-genome sequencing and RNA sequencing. The addition of whole transcriptome sequencing is particularly promising, as RNA expression data has guided nearly half of therapeutic recommendations in rare cancers. However, the upfront use of NGS fusion panels for all new sarcoma cases is discouraged, as most subtypes exhibit classic histologic features that don’t require NGS for diagnosis.
Interestingly, approximately two-thirds of sarcomas, especially those with complex karyotypes, are unlikely to harbor specific genetic alterations, making molecular testing redundant for these cases. Traditional methods like pathology, immunohistochemistry, and targeted tests often suffice. The clinical benefit rate from matched therapies post-NGS is a mere 0.4%, further questioning its routine use.
The Path Forward: Selective and Expert-Driven NGS
For managed care organizations, the consensus advocates for highly selective NGS use, reserving it for specific subtypes or scenarios where actionable alterations are likely. Patients should be referred to sarcoma-expert centers, where diagnostic accuracy is higher and NGS can be applied judiciously. This approach reduces misdiagnosis, cuts unnecessary costs, and improves outcomes. Crucially, NGS results must be interpreted by multidisciplinary tumor boards, integrating clinical, pathologic, and molecular data before treatment decisions.
A Call for Discussion
As we stand at the crossroads of innovation and practicality, the question remains: Is NGS a revolutionary tool or a prematurely adopted technology in sarcoma care? What do you think? Should we prioritize expanding molecular research or focus on refining existing diagnostic methods? Share your thoughts in the comments—let’s spark a conversation that could shape the future of sarcoma treatment.
